Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation-Reference-Cited by-同舟云学术

Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation

Published:2017-02 Issue:2 Volume:39 Page:370-377
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Scaglione Francesco,Donde Shaantanu,Hassan Tarek A.,Jannini Emmanuele A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference43 articles.

1. Impotence. NIH Consensus Development Panel on Impotence;Jama,1993

2. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences;Ayta;BJU Int,1999

3. Evaluation and management of erectile dysfunction in clinical practice;Brant;JCOM,2009

4. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction;Martin;J Sex Med,2013

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview of conventional and investigational phosphodiesterase 5 inhibitors for treating erectile dysfunction and other conditions;Expert Opinion on Investigational Drugs;2024-08-11

2. Association between air pollution and male sexual function: A nationwide observational study in China;Journal of Hazardous Materials;2024-05

3. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial;The Lancet Haematology;2024-05

4. LC-MS/MS methods for simultaneous determination of youkenafil and its metabolite M1 in human seminal plasma and plasma: Application to evaluate the acute effect of youkenafil on semen quality and its pharmacokinetics in human;Journal of Chromatography B;2024-04

5. Sildenafil in a new innovative dosage form (orodispersible film);Vnitřní lékařství;2024-02-26